Abstract
Background: Prader-Willi Syndrome (PWS) is a neurodevelopmental genomic imprinting disorder with lack of expression of genes inherited from the paternal chromosome 15q11-q13 region usually from paternal 15q11-q13 deletions (about 60%) or maternal uniparental disomy 15 or both 15s from the mother (about 35%). An imprinting center controls the expression of imprinted genes in the chromosome 15q11-q13 region. Key findings include infantile hypotonia, a poor suck, failure to thrive and hypogonadism/hypogenitalism. Short stature and small hands/feet due to growth and other hormone deficiencies, hyperphagia and marked obesity occur in early childhood, if uncontrolled. Cognitive and behavioral problems (tantrums, compulsions, compulsive skin picking) are common.
Objective: Hyperphagia and obesity with related complications are major causes of morbidity and mortality in PWS. This report will describe an accurate diagnosis with determination of specific genetic subtypes, appropriate medical management and best practice treatment approaches.
Methods and Results: An extensive literature review was undertaken related to genetics, clinical findings and laboratory testing, clinical and behavioral assessments and summary of updated health-related information addressing the importance of early PWS diagnosis and treatment. A searchable, bulleted and formatted list of topics is provided utilizing a Table of Contents approach for the clinical practitioner.
Conclusion: Physicians and other health care providers can use this review with clinical, genetic and treatment summaries divided into sections pertinent in the context of clinical practice. Frequently asked questions by clinicians, families and other interested participants or providers will be addressed.
Keywords: Diagnostic protocols, treatment approaches, genetic testing, genomic imprinting, medication, care management, obesity, caloric intake, Prader-Willi syndrome.
[1]
Butler MG. Prader-Willi syndrome: Current understanding of cause and diagnosis. Am J Med Genet 1990; 35: 319-32.
[2]
Butler MG, Lee PDK, Whitman BY. Management of Prader-Willi Syndrome. 3rd ed. New York, NY: Springer Verlag Inc. 2006.
[3]
Butler MG. Prader-Willi syndrome: Obesity due to genomic imprinting. Curr Genomics 2011; 12(3): 204-15.
[4]
Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. Genet Med 2012; 14: 10-26.
[5]
Angulo M, Butler MG, Cataletto M. Prader-Willi syndrome: A review of clinical, genetic and endocrine findings. J Endocrinol Invest 2015; 38(12): 1249-63.
[6]
Butler MG, Cassidy SB. Genetic basis, genetic testing and genetic counseling for Prader-Willi syndrome. In: Prader-Willi Syndrome. C. Hoybye (ed.). Nova Science Publishers Inc. Hauppauge, NY 2013.
[7]
Dykens EM. Are jigsaw puzzle skills ‘spared’ in persons with Prader-Willi syndrome? J Child Psychol Psychiatry 2002; 43(3): 343-52.
[8]
Roof E, Stone W, MacLean W, Feurer ID, Thompson T, Butler MG. Intellectual characteristics of Prader-Willi syndrome: comparison of genetic subtypes. J Intellect Disabil Res 2000; 44(Pt 1): 25-30.
[9]
Soni S, Whittington J, Holland AJ, et al. The course and outcome of psychiatric illness in people with Prader-Willi syndrome: implications for management and treatment. J Intellect Disabil Res 2007; 51(Pt 1): 32-42.
[10]
Soni S, Whittington J, Holland AJ, et al. The phenomenology and diagnosis of psychiatric illness in people with Prader-Willi syndrome. Psychol Med 2008; 38(10): 1505-14.
[11]
Butler MG, Bittel DC, Kibiryeva N, Talebizadeh Z, Thompson T. Behavioral differences among subjects with Prader-Willi syndrome and type I or type II deletion and maternal disomy. Pediatrics 2004; 113: 565-73.
[12]
Zarcone J, Napolitano D, Peterson C, et al. The relationship between compulsive behavior and academic achievement across the three genetic subtypes of Prader-Willi syndrome. J Intellect Disabil Res 2007; 51: 478-87.
[13]
Boer H, Holland A, Whittington J, Butler J, Webb T, Clarke D. Psychotic illness in people with Prader-Willi syndrome due to chromosome 15 maternal uniparental disomy. Lancet 2002; 359(9301): 135-6.
[14]
Holm VA, Cassidy SB, Butler MG, et al. Prader-Willi syndrome: Consensus diagnostic criteria. Pediatrics 1993; 91: 398-402.
[15]
Gunay-Aygun M, Schwartz S, Heeger S, O’Riordan MA, Cassidy SB. The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria. Pediatrics 2001; 108(5) E92
[16]
Ledbetter DH, Riccardi VM, Airhart SD, Strobel RJ, Keenan BS, Crawford JD. Deletions of chromosome 15 as a cause of the Prader-Willi syndrome. N Engl J Med 1981; 304(6): 325-9.
[17]
Butler MG, Palmer CG. Parental origin of chromosome 15 deletion in Prader-Willi syndrome. Lancet 1983; 1(8336): 1285-6.
[18]
Nicholls RD, Knoll JH, Butler MG, Karam S, Lalande M. Genetic imprinting suggested by maternal heterodisomy in nondeletion Prader-Willi syndrome. Nature 1989; 342: 281-5.
[19]
Ohta T, Gray TA, Rogan PK, et al. Imprinting-mutation mechanisms in Prader-Willi syndrome. Am J Hum Genet 1999; 64: 397-413.
[20]
Buiting K, Gross S, Lich C, Gillessen-Kaesbach G, el-Maarri O, Horsthemke B. Epimutations in Prader-Willi and Angelman syndromes: A molecular study of 136 patients with an imprinting defect. Am J Hum Genet 2003; 72(3): 571-7.
[21]
Bittel DC, Butler MG. Prader-Willi syndrome: Clinical genetics, cytogenetics and molecular biology. Expert Rev Mol Med 2005; 7: 1-20.
[22]
Newkirk HL, Bittel DC, Butler MG. Analysis of the Prader-Willi syndrome chromosome region using quantitative microsphere hybridization (QMH) array. Am J Med Genet A 2008; 146A(18): 2346-54.
[23]
Butler MG, Hartin SN, Hossain WA, et al. Molecular genetic classification in Prader-Willi syndrome: a multisite cohort study. J Med Genet 2019; 56(3): 149-53.
[24]
Goldstone AP, Holland AJ, Hauffa BP, et al. Recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin Endocrinol Metab 2008; 93(11): 4183-97.
[25]
McCandless SE, Saal HM, Braddock SR, et al. Clinical report— health supervision for children with Prader-Willi syndrome. Pediatrics 2011; 127(1): 195-204.
[26]
Miller JL, Lynn CH, Driscoll DC, et al. Nutritional phases in Prader-Willi syndrome. Am J Med Genet 2011; 155A: 1040-9.
[27]
Griggs J, Sinnayah P, Mathai ML. Prader-Willi syndrome: From genetics to behaviour, with special focus on appetite treatments. Neurosci Biobehav Rev 2015; 59: 155-72.
[28]
Hartin SN, Hossain WA, Weisensel N, Butler MG. Three siblings with Prader-Willi syndrome caused by imprinting center microdeletions and review. Am J Med Genet A 2018; 176(4): 886-95.
[29]
Butler MG, Christian SL, Kubota T, Ledbetter DH. A 5-year-old white girl with Prader-Willi syndrome and a submicroscopic deletion of chromosome 15q11q13. Am J Med Genet 1996; 65(2): 137-41.
[30]
Sahoo T, del Gaudio D, German JR, et al. Prader-Willi phenotype caused by paternal deficiency for the HBII-85 C/D box small nucleolar RNA cluster. Nat Genet 2008; 40(6): 719-21.
[31]
Kim SJ, Miller JL, Kuipers PJ, et al. Unique and atypical deletions in Prader-Willi syndrome reveal distinct phenotypes. Eur J Hum Genet 2012; 20(3): 283-90.
[32]
Butler MG, Sturich J, Myers SE, Gold JA, Kimonis V, Driscoll DJ. Is gestation in Prader-Willi syndrome affected by the genetic subtype? J Assist Reprod Genet 2009; 26(8): 461-6.
[33]
Gross N, Rabinowitz R, Gross-Tsur V, Hirsch HJ, Eldar-Geva T. Prader-Willi syndrome can be diagnosed prenatally. Am J Med Genet A 2015; 167A(1): 80-5.
[34]
Butler MG. Benefits and limitations of prenatal screening for Prader-Willi syndrome. Prenat Diagn 2017; 37(1): 81-94.
[35]
Butler MG. Single gene and syndromic causes of obesity: Illustrative examples. Prog Mol Biol Transl Sci 2016; 140: 1-45.
[36]
Butler MG, Meaney FJ, Palmer CG. Clinical and cytogenetic survey of 39 individuals with Prader-Labhart-Willi syndrome. Am J Med Genet 1986; 23(3): 793-809.
[37]
Butler MG, Thompson T. Prader-Willi syndrome: Clinical and genetic findings. Endocrinology 2000; 10: 2S-16S.
[38]
Butler MG, Weaver DD, Meaney FJ. Prader-Willi syndrome: Are there population differences? Clin Genet 1982; 22(5): 292-4.
[39]
Whittington J, Holland A, Webb T, Butler J, Clarke D, Boer H. Cognitive abilities and genotype in a population-based sample of people with Prader-Willi syndrome. J Intellect Disabil Res 2004; 48: 172-87.
[40]
Butler MG, Manzardo AM, Heinemann J, Loker C, Loker J. Causes of death in Prader-Willi syndrome: Prader-Willi Syndrome Association (USA) 40-year mortality survey. Genet Med 2017; 19(6): 635-42.
[41]
Butler MG, Fischer W, Kibiryeva N, Bittel DC. Array comparative genomic hybridization (aCGH) analysis in Prader-Willi syndrome. Am J Med Genet A 2008; 146A(7): 854-60.
[42]
Butler MG, Theodoro MF, Bittel DC, Kuipers PJ, Driscoll DJ, Talebizadeh Z. X-chromosome inactivation patterns in females with Prader-Willi syndrome. Am J Med Genet A 2007; 143A(5): 469-75.
[43]
Yang T, Adamson TE, Resnick JL, et al. A mouse model for Prader-Willi syndrome imprinting-centre mutations. Nat Genet 1998; 19(1): 25-31.
[44]
Francis SM, Sagar A, Levin-Decanini T, Liu W, Carter CS, Jacob S. Oxytocin and vasopressin systems in genetic syndromes and neurodevelopmental disorders. Brain Res 2014; 1580: 199-218.
[45]
Johnson L, Manzardo AM, Miller JL, Driscoll DJ, Butler MG. Elevated plasma oxytocin levels in children with Prader-Willi syndrome compared with healthy unrelated siblings. Am J Med Genet A 2016; 170(3): 594-601.
[46]
Butler MG, Nelson TA, Driscoll DJ, Manzardo AM. Evaluation of plasma substance P and beta-endorphin levels in children with Prader-Willi syndrome. J Rare Disease 2015; 3(2): 1-10.
[47]
Butler MG, Nelson TA, Driscoll DJ, Manzardo AM. High plasma neurotensin levels in children with Prader-Willi syndrome. Am J Med Genet A 2015; 167A(8): 1773-8.
[48]
Cruvinel E, Budinetz T, Germain N, Chamberlain S, Lalande M, Martins-Taylor K. Reactivation of maternal SNORD116 cluster via SETDB1 knockdown in Prader-Willi syndrome iPSCs. Hum Mol Genet 2014; 23(17): 4674-85.
[49]
Holsen LM, Zarcone JR, Brooks WM, et al. Neural mechanisms underlying hyperphagia in Prader-Willi syndrome. Obesity (Silver Spring) 2006; 14: 1028-37.
[50]
Cassidy SB, Lai LW, Erickson RP, et al. Trisomy 15 with loss of the paternal 15 as a cause of Prader-Willi syndrome due to maternal disomy. Am J Hum Genet 1992; 51(4): 701-8.
[51]
Butler MG. Genomic imprinting disorders in humans: A mini- review. J Assist Reprod Genet 2009; 26(9-10): 477-86.
[52]
Gold JA, Ruth C, Osann K, et al. Frequency of Prader-Willi syndrome in births conceived via assisted reproductive technology. Genet Med 2014; 16(2): 164-9.
[53]
Butler MG, Theodoro M, Skouse JD. Thyroid function studies in Prader-Willi syndrome. Am J Med Genet A 2007; 143A(5): 488-92.
[54]
Irizarry KA, Bain J, Butler MG, et al. Metabolic profiling in Prader-Willi syndrome and nonsyndromic obesity: sex differences and the role of growth hormone. Clin Endocrinol (Oxf) 2015; 83(6): 797-805.
[55]
Tan PL, Katsanis N. Thermosensory and mechanosensory perception in human genetic disease. Hum Mol Genet 2009; 18(R2): R146-55.
[56]
Butler MG, Hayes BG, Hathaway MM, Begleiter ML. Specific genetic diseases at risk for sedation/anesthesia complications. Anesth Analg 2000; 91(4): 837-55.
[57]
Stevenson DA, Heinemann J, Angulo M, et al. Gastric rupture and necrosis in Prader-Willi syndrome. J Pediatr Gastroenterol Nutr 2007; 45: 272-4.
[58]
Mahmoud R, Singh P, Weiss L, et al. Newborn screening for Prader-Willi syndrome is feasible: Early diagnosis for better outcomes. Am J Med Genet 2018; 1-8.
[59]
Lo ST, Collin PJ, Hokken-Koelega AC. Psychiatric disorders in children with Prader-Willi syndrome-Results of a 2-year longitudinal study. Am J Med Genet A 2015; 167A(5): 983-91.
[60]
Papenhausen P, Schwartz S, Risheg H, et al. UPD detection using homozygosity profiling with a SNP genotyping microarray. Am J Med Genet A 2011; 155A(4): 757-68.
[61]
Hartin SN, Hossain WA, Francis D, Godler DE, Barkataki S, Butler MG. Analysis of the Prader-Willi syndrome imprinting center using Droplet Digital PCR and next-generation whole-exome sequencing. Mol Genet Genomic 2019; e575 1-10.
[62]
Butler MG. Molecular diagnosis of Prader-Willi syndrome: comparison of cytogenetic and molecular genetic data including parent of origin dependent methylation DNA patterns. Am J Med Genet 1996; 61(2): 188-90.
[63]
Bittel DC, Kibiryeva N, Butler MG. Methylation-specific multiplex ligation-dependent probe amplification analysis of subjects with chromosome 15 abnormalities. Genet Test 2007; 11(4): 467-75.
[64]
Henkhaus RS, Kim SJ, Kimonis VE, et al. Methylation-specific multiplex ligation-dependent probe amplification and identification of deletion genetic subtypes in Prader-Willi syndrome. Genet Test Mol Biomarkers 2012; 16(3): 178-86.
[65]
Deal CL, Tony M, Hoybye C, Allen DB, Tauber M, Christiansen JS. Growth Hormone Research Society workshop summary: Consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab 2013; 98: E1072-87.
[66]
Butler MG, Haber L, Mernaugh R, Carlson MG, Price R, Feurer ID. Decreased bone mineral density in Prader-Willi syndrome: comparison with obese subjects. Am J Med Genet 2001; 103(3): 216-22.
[67]
Butler MG, Roberts J, Hayes J, Tan X, Manzardo AM. Growth hormone receptor (GHR) gene polymorphism and Prader-Willi syndrome. Am J Med Genet A 2013; 161A(7): 1647-53.
[68]
Butler MG, Sturich J, Lee J, et al. Growth standards of infants with Prader-Willi syndrome. Pediatrics 2011; 127(4): 687-95.
[69]
Butler MG, Lee J, Manzardo AM, et al. Growth charts for non- growth hormone treated Prader-Willi syndrome. Pediatrics 2015; 135: e126-35.
[70]
Butler MG, Lee J, Cox DM, et al. Growth charts for Prader-Willi syndrome during growth hormone treatment. Clin Pediatr (Phila) 2016; 55(10): 957-74.
[71]
Obrynba KS, Hoffman RP, Repaske DR, Anglin K, Kamboj MK. No central adrenal insufficiency found in patients with Prader-Willi syndrome with an overnight metyrapone test. J Pediatr Endocrinol Metab 2018; 31(7): 809-14.
[72]
de Lind van Wijngaarden RF, Otten BJ, Festen DA, et al. High prevalence of central adrenal insufficiency in patients with Prader-Willi syndrome. J Clin Endocrinol Metab 2008; 93(5): 1649-54.
[73]
Oto Y, Matsubara K, Ayabe T, et al. Delayed peak response of cortisol to insulin tolerance test in patients with Prader-Willi syndrome. Am J Med Genet A 2018; 176(6): 1369-74.
[74]
Grugni G, Sartorio A, Crinò A. Growth hormone therapy for Prader-Willi syndrome: challenges and solutions. Ther Clin Risk Manag 2016; 12: 873-81.
[75]
Corrias A, Grugni G, Crinò A, et al. Study Group for Genetic Obesity of Italian Society of Pediatric Endocrinology and Diabetology (SIEDP/ISPED). Assessment of central adrenal insufficiency in children and adolescents with Prader-Willi syndrome. Clin Endocrinol (Oxf) 2012; 76(6): 843-50.
[76]
Farholt S, Sode-Carlsen R, Christiansen JS, Østergaard JR, Høybye C. Normal cortisol response to high-dose synacthen and insulin tolerance test in children and adults with Prader-Willi syndrome. J Clin Endocrinol Metab 2011; 96(1): E173-80.
[77]
Edgar OS, Lucas-Herald AK, Shaikh MG. Pituitary-adrenal axis in Prader-Willi syndrome. Diseases 2016; 4(1) pii: E5
[78]
Jones KL, Ed. Smith’s Recognizable Patterns of Human Malformation. 6th ed. Philadelphia: W.B. Saunders Company 2006; pp. 1-954.
[79]
Choquet H, Meyre D. Genetics of obesity: What have we learned? Curr Genomics 2011; 12(3): 169-79.
[80]
Choquet H, Meyre D. Molecular basis of obesity: Current status and future prospects. Curr Genomics 2011; 12(3): 154-68.
[81]
Butler MG, Wang K, Marshall JD, et al. Coding and noncoding expression patterns associated with rare obesity-related disorders: Prader-Willi and Alström syndromes. Adv Genomics Genet 2015; 2015(5): 53-75.
[82]
Dasouki MJ, Youngs EL, Hovanes K. Structural chromosome abnormalities associated with obesity: report of four new subjects and review of literature. Curr Genomics 2011; 12(3): 190-203.
[83]
Butler MG, McGuire A, Manzardo AM. Clinically relevant known and candidate genes for obesity and their overlap with human infertility and reproduction. J Assist Reprod Genet 2015; 32(4): 495-508.
[84]
Butler MG. Management of obesity in Prader-Willi syndrome. Nat Clin Pract Endocrinol Metab 2006; 2(11): 592-3.
[85]
Salehi P, Leavitt A, Beck AE, Chen ML, Roth CL. Obesity management in Prader-Willi syndrome. Pediatr Endocrinol Rev 2015; 12(3): 297-307.
[86]
Emerick JE, Vogt KS. Endocrine manifestations and management of Prader-Willi syndrome. Int J Pediatr Endocrinol 2013; 2013(1): 14.
[87]
Sanchez-Ortiga R, Klibanski A, Tritos NA. Effects of recombinant human growth hormone therapy in adults with Prader-Willi syndrome: a meta-analysis. Clin Endocrinol 2012; 77: 86-93.
[88]
Smith T, Sharp S, Manzardo AM, Butler MG. Pharmacogenetics informed decision making in adolescent psychiatric treatment: a clinical case report. Int J Mol Sci 2015; 16(3): 4416-28.
[89]
Butler MG. Pharmacogenetics and psychiatric care: A review and commentary. J Mental Health & Clin Psychology 2018; 2(2): 17-24.
[90]
Espadaler J, Tuson M, Lopez-Ibor JM, Lopez-Ibor F, Lopez-Ibor MI. Pharmacogenetic testing for the guidance of psychiatric treatment: a multicenter retrospective analysis. CNS Spectr 2017; 22(4): 315-24.
[91]
de Lind van Wijngaarden RF, Siemensma EP, Festen DA, et al. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome. J Clin Endocrinol Metab 2009; 94: 4205-15.
[92]
Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, et al. Beneficial effects of growth hormone treatment on cognition in children with Prader-Willi syndrome: A randomized controlled trial and longitudinal study. J Clin Endocrinol Metab 2012; 97: 2307-14.
[93]
Miller JL, Angulo M. An open-label pilot study of N-acetylcysteine for skin-picking in Prader-Willi syndrome. Am J Med Genet A 2014; 164A(2): 421-4.
[94]
Bravo GL, Poje AB, Perissinotti I, et al. Transcranial direct current stimulation reduces food-craving and measures of hyperphagia behavior in participants with Prader-Willi syndrome. Am J Med Genet B Neuropsychiatr Genet 2016; 171B(2): 266-75.
[95]
McCandless SE, Yanovski JA, Miller J, et al. Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2017; 19(12): 1751-61.
[96]
Miller JL, Tamura R, Butler MG, et al. Oxytocin treatment in children with Prader-Willi syndrome: A double-blind, placebo-controlled, crossover study. Am J Med Genet A 2017; 173(5): 1243-50.
[97]
Kido Y, Sakazume S, Abe Y, Oto Y, et al. Testosterone replacement therapy to improve secondary sexual characteristics and body composition without adverse behavioral problems in adult male patients with Prader-Willi syndrome: An observational study. Am J Med Genet A 2013; 161A(9): 2167-73.
[98]
Davenport ML, Roush J, Liu C, et al. Growth hormone treatment does not affect incidences of middle ear disease or hearing loss in infants and toddlers with Turner syndrome. Horm Res Paediatr 2010; 74(1): 23-32.
[99]
Blunden C, Nasomyont N, Backeljauw P. Growth hormone therapy for Turner syndrome. Pediatr Endocrinol Rev 2018; 16(Suppl. 1): 80-90.
[100]
Gross-Tsur V, Hirsch HJ, Benarroch F, Eldar-Geva T. The FSH-inhibin axis in Prader-Willi syndrome: heterogeneity of gonadal dysfunction. Reprod Biol Endocrinol 2012; 10: 39.
[101]
Shapira NA, Lessig MC, He AG, James GA, Driscoll DJ, Liu Y. Satiety dysfunction in Prader-Willi syndrome demonstrated by fMRI. J Neurol Neurosurg Psychiatry 2005; 76(2): 260-2.
[102]
Shapira NA, Lessig MC, Murphy TK, Driscoll DJ, Goodman WK. Topiramate attenuates self-injurious behaviour in Prader-Willi syndrome. Int J Neuropsychopharmacol 2002; 5(2): 141-5.
[103]
Butler MG, Hossain W, Hassan M, Manzardo AM. Growth hormone receptor (GHR) gene polymorphism and scoliosis in Prader-Willi syndrome. Growth Horm IGF Res 2018; 39: 29-33.
[104]
Brunetti G, Grugni G, Piacente L, et al. Analysis of circulating mediators of bone remodeling in Prader-Willi syndrome. Calcif Tissue Int 2018; 102(6): 635-43.
[105]
Yang L, Zhan GD, Ding JJ, et al. Psychiatric illness and intellectual disability in the Prader-Willi syndrome with different molecular defects--a meta-analysis. PLoS One 2013; 8(8) e72640
[106]
Ogata H, Ihara H, Murakami N, Gito M, Kido Y, Nagai T. Autism spectrum disorders and hyperactive/impulsive behaviors in Japanese patients with Prader-Willi syndrome: a comparison between maternal uniparental disomy and deletion cases. Am J Med Genet A 2014; 164A(9): 2180-6.
[107]
Doe CM, Relkovic D, Garfield AS, et al. Loss of the imprinted snoRNA mbii-52 leads to increased 5htr2c pre-RNA editing and altered 5HT2CR-mediated behaviour. Hum Mol Genet 2009; 18(12): 2140-8.
[108]
Larson FV, Whittington J, Webb T, Holland AJ. A longitudinal follow-up study of people with Prader-Willi syndrome with psychosis and those at increased risk of developing psychosis due to genetic subtype. Psychol Med 2014; 44(11): 2431-5.
[109]
Manzardo AM, Weisensel N, Ayala S, Hossain W, Butler MG. Prader-Willi syndrome genetic subtypes and clinical neuropsychiatric diagnoses in residential care adults. Clin Genet 2018; 93(3): 622-31.
[110]
Manzardo AM, Loker J, Heinemann J, Loker C, Butler MG. Survival trends from the Prader-Willi Syndrome Association (USA) 40-year mortality survey. Genet Med 2018; 20(1): 24-30.
Related Journals
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Diabetes Reviews
Current Neurovascular Research
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
Current Stem Cell Research & Therapy
Current Alzheimer Research
Current HIV Research
Current Aging Science
Related Books
Textbook of Advanced Dermatology: Pearls for Academia and Skin Clinics (Part 1)
The NLRP3 Inflammasome: An Attentive Arbiter of Inflammatory Response
Morphea and Related Disorders
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Stem Cells in Clinical Application and Productization
Marine Biopharmaceuticals: Scope and Prospects
Frontiers in Clinical Drug Research - Anti-Cancer Agents
Handbook of Laparoscopy Instruments
Optical Coherence Tomography Angiography for Choroidal and Vitreoretinal Disorders – Part 2
Female Arousal and Orgasm: Anatomy, Physiology, Behaviour and Evolution
Article Metrics
314
34
2
